Retatrutide vs Tirzepatide: The Triple-Agonist Question
Retatrutide is a pre-approval triple agonist of the GIP, GLP-1 and glucagon receptors. On paper it adds a third metabolic lever to the dual-agonist architecture pioneered by tirzepatide. The phase 2 data are striking; the open questions about glucagon agonism in humans are substantial.
incretin and counter-regulatory receptors engaged by retatrutide vs two for tirzepatide and one for semaglutide.
mean body-weight change at 48 weeks on retatrutide 12 mg in the phase 2 obesity trial.
retatrutide is in late-stage development; TRIUMPH phase 3 programme is ongoing as of 2025.
the novel receptor target — known to influence hepatic glucose output and energy expenditure.
Tirzepatide is an approved dual GIP/GLP-1 agonist with the deepest published evidence base outside semaglutide. Retatrutide adds glucagon receptor agonism, theoretically increasing energy expenditure and hepatic fat handling at the cost of more complex glucose physiology. Phase 2 weight outcomes exceed tirzepatide's pivotal data, but the comparison is not yet head-to-head and long-term safety, cardiovascular and hepatic data are pending.
Adding glucagon agonism is not a bigger version of GLP-1 — it is a different metabolic shape, with different upsides and different risks.
What they are
Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist of the GIP and GLP-1 receptors, administered weekly. Approved for type 2 diabetes (Mounjaro) and obesity (Zepbound).
Retatrutide is a synthetic peptide engineered as a co-agonist of the GIP, GLP-1 and glucagon receptors — a 'triple G' incretin/counter-regulatory agonist. Investigational at time of writing; phase 2 data published 2023, phase 3 TRIUMPH programme ongoing.
The pharmacological rationale for adding glucagon agonism is that glucagon increases hepatic glucose output and energy expenditure; balanced against incretin-driven insulin secretion, the net effect in animal models is greater weight loss and lipid handling than dual agonism alone.
Where they diverge
| Layer | What the research describes |
|---|---|
| GLP-1 receptor | Both agonist — appetite, satiety, glucose-dependent insulin secretion. |
| GIP receptor | Both agonist — incretin amplification, complementary signalling to GLP-1. |
| Glucagon receptor | Retatrutide only — hepatic glucose output, energy expenditure, lipid mobilisation. |
| Energy expenditure | Tirzepatide modest; retatrutide hypothesised larger via glucagon contribution. |
| Glycaemic balance | Tirzepatide net insulin-secretagogue; retatrutide must balance glucagon's hyperglycaemic effect against incretin-driven insulin response. |
Triple agonism is not just 'one more receptor'. Glucagon and GLP-1 oppose each other on glucose; the pharmacology has to keep that balance.
Phase 2 vs pivotal trial data
Retatrutide phase 2 (obesity)
48-week trial in adults with obesity, no diabetes. Mean weight change −24.2% on 12 mg vs −2.1% on placebo (NEJM, 2023).
Tirzepatide SURMOUNT-1
72-week trial, same population. Mean weight change −20.9% on 15 mg vs −3.1% on placebo (NEJM, 2022).
Direct comparison status
No head-to-head trial published as of 2025. Cross-trial comparison is not a fair maximum-dose comparison; trial design, duration and populations differ.
The retatrutide phase 2 weight effect at 48 weeks already exceeds tirzepatide's 72-week pivotal endpoint, with the curve still descending. That is striking but not decisive: phase 2 trials select more responsive populations, durations differ, and only TRIUMPH phase 3 can answer the long-horizon question.
The harder question is glucagon-driven safety. Glucagon agonism affects hepatic glucose output, may influence resting heart rate, and has historically been the source of failures in earlier triple-agonist programmes. Long-term cardiovascular and hepatic data are the read-outs that matter.
What we know, what's still open
- Mechanism: Both molecules are well-characterised at the receptor level; triple agonism is supported by binding and preclinical metabolic data.
- Weight efficacy: Tirzepatide mature phase 3 data; retatrutide compelling phase 2 only.
- Glycaemic efficacy: Tirzepatide proven in SURPASS programme; retatrutide phase 2 T2D data favourable but smaller.
- Cardiovascular outcomes: Tirzepatide SURPASS-CVOT ongoing; retatrutide CV outcome programme yet to read out.
- Approval status: Tirzepatide approved (EU/UK/US); retatrutide investigational, no approved indication.
Frequently asked
Is retatrutide simply 'stronger' tirzepatide?
No. It is a different molecule engaging a third receptor (glucagon) with its own metabolic physiology. Larger phase 2 effects reflect different pharmacology, not a higher dose of the same drug.
When might retatrutide be approved?
Phase 3 TRIUMPH read-outs are expected across 2025–2027. Regulatory approval — if positive — would follow that timeline.
Why add glucagon at all?
Glucagon increases energy expenditure and hepatic lipid mobilisation. Balanced against incretin insulin secretion, the net effect in models is greater weight loss and improved hepatic steatosis markers.
Should this change tirzepatide decisions today?
No. Investigational molecules don't displace approved ones with mature safety data. Treatment decisions belong with a treating clinician working from current evidence.
Where to read further
- • Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — phase 2 trial. NEJM 2023;389:514–526.
- • Rosenstock J et al. Retatrutide for type 2 diabetes — phase 2 trial. Lancet 2023.
- • Jastreboff AM et al. SURMOUNT-1. NEJM 2022;387:205–216.
- • Frias JP et al. Tirzepatide vs semaglutide (SURPASS-2). NEJM 2021;385:503–515.